Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA.
Toxicon. 2013 Jun 1;67:81-6. doi: 10.1016/j.toxicon.2012.11.024. Epub 2013 Jan 30.
Comparative literature assessing the relative safety and efficacy of different BoNT products is limited. The quantity and quality of data vary by preparation and indication. Clinicians seeking data relevant to the care of patients with specific conditions may find only reports about small numbers of patients with varying symptoms. While a literature search for "botulinum neurotoxins" will yield a large number of publications; only a fraction of these meet criteria for an academic evidence-based review. Patients may have been treated with a different BoNT formulation than that with which the physician is familiar, or there may be little or no clinical data on the use of a specific BoNT product for the proposed intervention. This paper is an introduction to a series of papers (which follow) in which an expert panel reviewed the BoNT clinical trial literature in order to provide evidence-based recommendations regarding the clinical use and efficacy of available BoNT preparations for four major therapeutic areas: movement disorders, spasticity, urology, and secretory disorders. Expert opinion is also included to address practical issues where more evidence and further research is needed.
比较文学评估不同 BoNT 产品的相对安全性和疗效的研究有限。数据的数量和质量因制剂和适应证而异。临床医生在寻找与特定疾病患者护理相关的数据时，可能只能找到关于少数具有不同症状患者的报告。虽然对“肉毒神经毒素”的文献搜索会产生大量出版物；但其中只有一小部分符合学术循证综述的标准。患者接受的 BoNT 制剂可能与医生熟悉的制剂不同，或者对于特定 BoNT 产品用于拟议干预的临床数据很少或没有。本文是一系列论文（随后）的介绍，一个专家小组审查了 BoNT 临床试验文献，以便就可用 BoNT 制剂在四个主要治疗领域（运动障碍、痉挛、泌尿科和分泌障碍）的临床应用和疗效提供循证建议。专家意见也包括在需要更多证据和进一步研究的实际问题上。
